A global randomized Phase 3 trial evaluating talimogene laherparepvec in combination with Pembrolizumab (KEYTRUDA) in patients with regionally or distantly metastatic melanoma

Trial Profile

A global randomized Phase 3 trial evaluating talimogene laherparepvec in combination with Pembrolizumab (KEYTRUDA) in patients with regionally or distantly metastatic melanoma

Planning
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top